# Cinclus Pharma Holding > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/cincluspharmaholding). ## Overview Cinclus Pharma Holding AB is a Swedish pharmaceutical company focused on developing and commercializing innovative treatments for gastroesophageal reflux disease (GERD). Established in Stockholm, the company is publicly listed on Nasdaq Stockholm and is advancing its drug candidate, linaprazan glurate, through clinical trials. Cinclus Pharma aims to address significant unmet medical needs in acid-related diseases through its specialized drug development efforts. ## Products & services • Linaprazan glurate for GERD • Clinical trial management • Regulatory strategy development • Pharmaceutical commercialization • Research and development in acid-related diseases - **Pharmaceutical Development** (70%) — Development of new drug candidates for acid-related diseases - **Clinical Trials** (20%) — Management and execution of clinical trials for drug candidates - **Regulatory Strategy** (10%) — Development of strategies for regulatory approval and compliance - Linaprazan glurate for GERD - Clinical trial management - Regulatory strategy development - Pharmaceutical commercialization - Research and development in acid-related diseases ## Customers Cinclus Pharma primarily serves healthcare providers and pharmaceutical distributors who require innovative treatments for gastroesophageal reflux disease. The company's drug candidates are aimed at addressing unmet medical needs, making them attractive to hospitals and clinics seeking effective GERD treatments. Additionally, Cinclus Pharma collaborates with research institutions and regulatory bodies to ensure compliance and efficacy of its products. The focus on specialized pharmaceuticals positions the company as a key partner for healthcare systems looking to improve patient outcomes in acid-related diseases. - **Healthcare Providers** (primary) — Purchase GERD treatments for patient care - **Pharmaceutical Distributors** (secondary) — Distribute innovative drugs to healthcare systems - **Research Institutions** (emerging) — Collaborate on clinical trials and drug development - Healthcare providers seeking effective GERD treatments - Pharmaceutical distributors interested in innovative drugs - Hospitals and clinics addressing unmet medical needs - Research institutions collaborating on clinical trials - Regulatory bodies ensuring drug compliance and efficacy ## Geography Cinclus Pharma is headquartered in Stockholm, Sweden, and operates primarily within the European market. The company's strategic location in Sweden allows it to leverage the robust pharmaceutical and healthcare ecosystem in the region. While its primary focus is on the European market, Cinclus Pharma is exploring opportunities for expansion into other regions with significant unmet medical needs for GERD treatments. The company's geographic presence is crucial for accessing key markets and regulatory bodies that facilitate drug approval and distribution. - Headquartered in Stockholm, Sweden - Primary operations in the European market - Exploring expansion opportunities in other regions - Strategic location for accessing key healthcare ecosystems ## Strategy Cinclus Pharma's strategic priorities include advancing its lead drug candidate, linaprazan glurate, through Phase III clinical trials and securing regulatory approvals. The company is focused on addressing significant unmet medical needs in GERD, which positions it for growth in the pharmaceutical market. Strategic partnerships and collaborations are key to Cinclus Pharma's approach, enabling it to leverage external expertise and resources. The company is also committed to expanding its geographic reach to tap into new markets and increase its competitive advantage. - **Advance Phase III Trials** (medium-term) — To bring linaprazan glurate to market - **Regulatory Approvals** (medium-term) — To ensure market entry and compliance - **Geographic Expansion** (long-term) — To access new markets and increase revenue - Advance linaprazan glurate through Phase III trials - Secure regulatory approvals for drug candidates - Address unmet medical needs in GERD - Form strategic partnerships and collaborations - Expand geographic reach to new markets ## Risks Cinclus Pharma faces several risks, including regulatory hurdles that could delay drug approvals and market entry. The company is also exposed to financial risks related to its reliance on equity financing, which may not be sustainable in the long term. Additionally, the competitive landscape in the pharmaceutical industry poses a risk, as larger companies may develop similar treatments. Market acceptance of new drugs is another critical risk, as it depends on the perceived effectiveness and safety of the treatments. Lastly, geopolitical risks, particularly in regions where the company seeks to expand, could impact operations and market access. - **Regulatory Approval Delays** [high] — Could impact market entry and revenue - **Equity Financing Reliance** [medium] — May not be sustainable long-term - **Competitive Landscape** [medium] — Larger companies may develop similar treatments - **Market Acceptance** [high] — Depends on perceived effectiveness of new drugs - Regulatory hurdles delaying drug approvals - Reliance on equity financing for operations - Competitive landscape with larger pharmaceutical companies - Market acceptance of new drug treatments - Geopolitical risks affecting market access ## Accounting Cinclus Pharma's financial statements are significantly impacted by the timing of revenue recognition, particularly as it pertains to milestone payments from partnerships and collaborations. The company must also consider the valuation of its drug development costs, which can affect reported earnings. Lease accounting under IFRS 16 is relevant due to the company's office and laboratory leases, impacting both assets and liabilities on the balance sheet. Additionally, the company must carefully manage estimates and provisions related to clinical trial costs and potential liabilities. These accounting matters are critical for investors to understand the financial health and operational progress of the company. - **Revenue Recognition** - **Drug Development Costs** - **Lease Accounting (IFRS 16)** - **Estimates and Provisions** - Revenue recognition timing affects milestone payments - Valuation of drug development costs impacts earnings - Lease accounting under IFRS 16 affects balance sheet - Estimates and provisions for clinical trial costs --- *Last updated: 2026-08-11T04:04:51.595920+00:00*